Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.95 USD | +0.72% | -13.66% | -43.22% |
05-09 | Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System | CI |
05-07 | Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-43.22% | 384M | |
+8.88% | 221B | |
+8.68% | 186B | |
+14.25% | 137B | |
+28.18% | 109B | |
+14.65% | 52.68B | |
+4.48% | 50.86B | |
+4.39% | 42.53B | |
+7.00% | 37.76B | |
+26.06% | 31.86B |
- Stock Market
- Equities
- PLSE Stock
- News Pulse Biosciences, Inc.
- Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise